Bioatla Inc. has received FDA clearance of its IND application to evaluate BA-3182, a conditionally active biologic (CAB) EpCAM/CD3 bispecific T-cell engager antibody, for the treatment of advanced adenocarcinoma. The company plans to initiate a phase I study this year.
Ocean Biomedical Inc. has discovered bispecific antibodies that target Chitinase 3-like-1 (CHI3L1) and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant melanoma cells to the lung by over 90%.
Ewing sarcoma has a poor prognosis, in part due to the small number of active natural killer (NK) cells and lack of specific tumor targeting. Interleukin 1 receptor accessory protein (IL1RAP) has been reported to be highly expressed in Ewing sarcoma cells but minimally expressed in normal tissues. Researchers have designed an NK cell-based CAR approach targeting ILRAP1 for the treatment of Ewing sarcoma.
Hangzhou Healzen Therapeutics Co. Ltd. has synthesized programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer, infections, immunological and inflammatory disorders.
Over half of the children with high-risk neuroblastoma experience late relapses caused by minimal residual disease. Since chimeric antigen receptor (CAR) T-cell therapy has shown efficacy against minimal residual disease in pediatric patients with hematologic malignancies, several CAR T-cell therapies are being investigated for neuroblastoma.
Mesothelin (MSLN) glycoprotein is overexpressed in many solid tumors and is considered a relevant target for antigen-specific therapies. In fact, chimeric antigen receptor (CAR) T-cell therapy against MSLN has shown promising results in preclinical models, as well as safety in a phase I trial.
Researchers from Caribou Biosciences Inc. presented preclinical data for the novel BCMA-specific allogeneic CAR T-cell therapy candidate, CB-011, being developed for the treatment of relapsed or refractory multiple myeloma. A genome editing strategy was implemented in the production of CB-011 to blunt CAR T-cell rejection by both patient T cells and natural killer (NK) cells.
Tumor-specific CD8 T cells play a prominent role in antitumor immunity. However, these cells regularly enter a state of exhaustion due to chronic antigen stimulation within the tumor microenvironment.
Oncolytic virus immunotherapy has been proposed as a step forward for cancer treatment because it can kill cancer cells while activating the immune system. However, its current clinical application is limited because targeting deep-seated cancers is challenging and because the complement and innate immunity rapidly clear oncolytic viruses administered systemically.
RSS
